Upadacitinib Market Report 2026

The upadacitinib market size has grown rapidly in recent years. It will grow from $1.5 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing prevalence of rheumatoid arthritis, limitations of conventional dmards, growing demand for targeted therapies, availability of oral treatment options, expansion of specialty care services.

The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing clinical approvals for new indications, rising focus on personalized autoimmune treatment, expansion of oral immunotherapy pipelines, growing investments in inflammatory disease research, increasing adoption of advanced small molecule drugs. Major trends in the forecast period include increasing adoption of jak inhibitor therapies, rising preference for oral targeted treatments, growing use of small molecule immunomodulators, expansion of autoimmune disease indications, enhanced focus on long-term disease management.

The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells, perceiving them as foreign invaders. Factors contributing to the rise in autoimmune diseases include genetic predisposition, environmental triggers, and changes in lifestyle and immune system function. Upadacitinib treats autoimmune conditions by selectively targeting and inhibiting JAK1, reducing inflammation and modulating the immune response in diseases such as rheumatoid arthritis and psoriatic arthritis. For example, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females were projected to have rheumatoid arthritis (RA) in 2025, with numbers expected to increase by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising incidence of autoimmune diseases is propelling the growth of the upadacitinib market.

Leading companies in the upadacitinib market are focusing on developing innovative therapies such as oral Janus kinase (JAK) inhibitors to expand treatment options for autoimmune diseases. Oral JAK inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing immune overactivation and inflammation, and effectively managing autoimmune and inflammatory conditions. For instance, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) received European Commission approval for treating moderately to severely active Crohn’s disease. The oral formulation allows once-daily dosing, improving patient convenience and adherence. This delivery method provides a faster onset of action compared to traditional therapies, making it easier for patients to follow their prescribed treatment plans.

In March 2023, AbbVie Inc., a US-based pharmaceutical company, partnered with Lupus Therapeutics for a Phase 3 clinical program evaluating upadacitinib in systemic lupus erythematosus (SLE). Through this collaboration, AbbVie aims to utilize Lupus Therapeutics’ network and expertise in patient recruitment, site activation, and engagement to accelerate the assessment of upadacitinib for an additional autoimmune indication. Lupus Therapeutics LLC, a US-based company, specializes in advancing lupus treatments by managing clinical research and trials.

Major companies operating in the upadacitinib market are AbbVie Inc, Pfizer Inc, Eli Lilly and Company, Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Bristol‑Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, AstraZeneca PLC, Gilead Sciences Inc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co Ltd, Galapagos NV, UCB SA, Daiichi Sankyo Company Ltd, Horizon Therapeutics plc, Regeneron Pharmaceuticals Inc.

North America was the largest region in the upadacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the upadacitinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the upadacitinib market by increasing costs of imported active pharmaceutical ingredients, formulation chemicals, manufacturing equipment, and packaging materials used in drug production. Pharmaceutical companies in North America and Europe are most affected due to reliance on global API supply chains, while Asia-Pacific faces pricing pressure on drug exports. These tariffs are increasing production costs and influencing pricing strategies. However, they are also encouraging domestic API manufacturing, localized drug production, and investment in regional pharmaceutical supply resilience.

The upadacitinib market research report is one of a series of new reports that provides upadacitinib market statistics, including upadacitinib industry global market size, regional shares, competitors with a upadacitinib market share, detailed upadacitinib market segments, market trends and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Upadacitinib is a Janus kinase (JAK) inhibitor that treats various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. Upadacitinib serves as an alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, providing targeted therapy with the convenience of oral administration.

The main product categories of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors are medications that block the activity of JAK enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used in various applications such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by different end-users, including hospitals, home care, specialty clinics, and others.

The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.